ASCO® 2023 Insights: "Final Analysis of Distant Metastasis-Free Survival in the Phase 3 KEYNOTE-716 Study - Pembro vs. Placebo as Adjuvant Therapy in Stage IIB/IIC Melanoma"

941 views
June 8, 2023
1 Comment
Login to view comments. Click here to Login